🇺🇸 FDA
Patent

US 10155039

Stable aqueous formulations of adalimumab

granted A61KA61K2039/505A61K2039/542

Quick answer

US patent 10155039 (Stable aqueous formulations of adalimumab) held by Coherus BioSciences, Inc. expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Coherus BioSciences, Inc.
Grant date
Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/542, A61K2039/545, A61K39/39533